Outcome of Board Meeting

Ref: Outcome/19.06.2026 June 19, 2026 The General Manager The Manager Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India P. J. Towers, Limited Dalal Street, Exchange Plaza, Plot No. C-1, G Mumbai – 400001. Block, Scrip Code: 524075 Bandra Kurla Complex, Bandra (East), Mumbai – 400051. Symbol: ALBERTDAVD Dear Sir / Madam, Sub: Outcome of the Board Meeting held on Friday, June, 19, 2026 In terms of Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”), we wish to inform you that the Board of Directors of the Company at its meeting held today, i.e. June 19, 2026, has approved the following matters:- 1. Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Amit Mahla (DIN: 11767012) (who was appointed as CEO of the company w.e.f 12th May, 2026) as an Additional Director on the Board of the Company with immediate effect, i.e. from June 19, 2026 and shall hold such office till the date of the 87th Annual General Meeting (AGM) and shall continue to hold office thereafter, subject to approval of the shareholders at the 87th AGM of the Company. 2. Based on the recommendation of the Nomination and Remuneration Committee & Audit Committee, the Board has approved the appointment of Mr. Amit Mahla (DIN: 11767012) (who was appointed as CEO of the company w.e.f 12th May, 2026) as Whole-time Director & CEO of the Company for a period of 5 years w.e.f. 19 June, 2026 to 18th June 2031 and fixed his remuneration for the period from June 19, 2026 to 31st March, 2027, both subject to approval of the shareholders at the 87th AGM of the Company. 3. The Board of Directors today revised Notice of 87th AGM to cover matters related to shareholders approval for regularisation, appointment and fixation of remuneration of Mr. Amit Mahla (DIN: 11767012) ( as explained in point 1 and 2 above) as Whole-time Director & CEO of the company. The date of 87th AGM, record date fixed for the purpose of payment of final Dividend and determining members eligible to vote at 87th AGM and Book Closure date fixed earlier remains unchanged. The details as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 is annexed herewith as Annexure-A. The meeting of the Board of Directors commenced at 10:40 A.M. and discussions on the above agenda items concluded at 04:15 P:M. The above information is also available on the website of the Company at www.albertdavidindia.com. We request you to take the above on record. Thanking you, Yours faithfully, For Albert David Limited Lalit Lohia Company Secretary & Compliance Officer Encl.: Annexure – A Annexure - A Details as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 are as under:- S/l Particulars Details of appointment of Mr. Amit Mahla, CEO (DIN: 11767012) as an Additional Director and Whole-time Director & CEO 1. Reason for change viz. The Board appointed Mr. Amit Mahla, CEO (DIN: appointment, resignation, 11767012) as an Additional Director w.e.f 19th June, 2026 removal, death or and as Whole-time Director & CEO of the Company for otherwise. a period of 5 years w.e.f 19th June, 2026 to 18th June, 2031, subject to approval of shareholders at 87th AGM of the company. 2. Date of as an Additional Director w.e.f 19th June, 2026 and as appointment/cessation Whole-time Director & CEO of the Company for a (as applicable) & term of period of 5 years w.e.f 19th June, 2026 to 18th June, 2031 appointment. 3. Brief profile (in case of Mr. Amit Mahla, aged 52 Years (approx.), is a seasoned appointment) leader with over 28 years of experience, recognized for transforming underperforming businesses into high growth engines. He holds a degree in Science, a postgraduate degree in English Literature, and an Executive MBA (Rank Holder) from SIES, Mumbai. He has led large, P&L-driven portfolios across leading organizations, including Cipla, Emcure, Glenmark, Alembic, Sun Pharma, and JB Pharma. He also brings entrepreneurial leadership experience, having worked with a start-up in Innovcare life sciences. Prior to joining Albert David, he was associated with JB Pharma. He possesses extensive expertise across both acute and chronic segments of the Indian Pharmaceutical Market (IPM), with a strong focus on business transformation and strategic leadership. He has contributed to building over 20 big brands across key therapy areas. He successfully led the integration of Sanzyme into JB Pharma—one of the most significant acquisitions in the IPM in recent times —ensuring seamless portfolio alignment, effective field-force integration, and sustained post-acquisition growth while unlocking strategic synergies. He has consistently demonstrated his ability to turn around challenging businesses, drive new business launches, introduce successful new products, create new categories, and provide thought leadership. 4. Disclosure of Mr. Amit Mahla is not relative of any director or key relationships between managerial personnel of the Company. directors (in case of appointment of a director). 5. Information required as Mr. Amit Mahla is not debarred from holding the office of under Circular No. Director by virtue of any order of the Securities and LIST/COMP/14/2018-19 Exchange Board of India (SEBI) or any other such authority. and NSE/CML/2018/24 dated June 20, 2018 issued by the BSE and NSE respectively. For Albert David Limited Lalit Lohia Company Secretary & Compliance Officer